Summary of Research: Elranatamab Fixed Dosing—A Safe, Effective, and Convenient Dosing Approach
Oncology and Therapy · 2026-03 · 14 (1) · 91-94
DOI: 10.1007/s40487-026-00415-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology and Therapy, online erschienen am 02.03.2026. Verfasst von Mohamed Elmeliegy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Research and Development, Pfizer, Inc., San Diego, CA, USA. Mohamed.Elmeliegy@pfizer.com. Die Arbeit nennt 1 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Oncology Research and Development, Pfizer, Inc., San Diego, CA, USA. Mohamed.Elmeliegy@pfizer.com.
- Oncology Research and Development, Pfizer, Inc., San Diego, CA, USA.
- Pfizer Research and Development, Pfizer, Inc., San Diego, CA, USA.
- Pfizer Global Medical Strategy, Pfizer Ltd, London, UK.
Förderung
- Pfizer
Zitieren
APA
Elmeliegy, M., Soltantabar, P., Hibma, J., Ashman, O., Wang, D., & Lon, H. K. (2026). Summary of Research: Elranatamab Fixed Dosing—A Safe, Effective, and Convenient Dosing Approach. Oncology and Therapy, 14(1), 91-94. https://doi.org/10.1007/s40487-026-00415-0
Vancouver
Elmeliegy M, Soltantabar P, Hibma J, Ashman O, Wang D, Lon HK. Summary of Research: Elranatamab Fixed Dosing—A Safe, Effective, and Convenient Dosing Approach. Oncology and Therapy. 2026;14(1):91-94. doi:10.1007/s40487-026-00415-0
BibTeX
@article{Elmeliegy2026,
author = {Elmeliegy, Mohamed and Soltantabar, Pooneh and Hibma, Jennifer and Ashman, Olivia and Wang, Diane and Lon, Hoi-Kei},
title = {Summary of Research: Elranatamab Fixed Dosing—A Safe, Effective, and Convenient Dosing Approach},
journal = {Oncology and Therapy},
year = {2026},
volume = {14},
number = {1},
pages = {91--94},
doi = {10.1007/s40487-026-00415-0}
}
EUVIMED